JP2023529640A5 - - Google Patents
Info
- Publication number
- JP2023529640A5 JP2023529640A5 JP2022574600A JP2022574600A JP2023529640A5 JP 2023529640 A5 JP2023529640 A5 JP 2023529640A5 JP 2022574600 A JP2022574600 A JP 2022574600A JP 2022574600 A JP2022574600 A JP 2022574600A JP 2023529640 A5 JP2023529640 A5 JP 2023529640A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate according
- group
- targeting agent
- cancer
- dendrimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901833 | 2020-06-03 | ||
| AU2020901833A AU2020901833A0 (en) | 2020-06-03 | Therapeutic conjugates | |
| PCT/AU2021/050554 WO2021243415A1 (en) | 2020-06-03 | 2021-06-03 | Therapeutic conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529640A JP2023529640A (ja) | 2023-07-11 |
| JP2023529640A5 true JP2023529640A5 (enExample) | 2024-06-10 |
Family
ID=78831413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574600A Pending JP2023529640A (ja) | 2020-06-03 | 2021-06-03 | 治療用コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240293588A1 (enExample) |
| JP (1) | JP2023529640A (enExample) |
| KR (1) | KR20230065935A (enExample) |
| CN (1) | CN115989039A (enExample) |
| AU (1) | AU2021284918A1 (enExample) |
| CA (1) | CA3180877A1 (enExample) |
| WO (1) | WO2021243415A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180326081A1 (en) * | 2011-06-06 | 2018-11-15 | Starpharma Pty Ltd | Macromolecules |
| WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
| WO2024007034A2 (en) * | 2022-07-01 | 2024-01-04 | The Johns Hopkins University | Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and other cancers in the brain |
| EP4661914A1 (en) * | 2023-02-09 | 2025-12-17 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates via inverse electron demand diels-alder reactions |
| WO2026046228A1 (zh) * | 2024-08-27 | 2026-03-05 | 苏州拓界医药有限公司 | 树枝状聚合物偶联物及其制备方法 |
| CN120718105A (zh) * | 2025-04-23 | 2025-09-30 | 湖南中晟全肽生物科技股份有限公司 | 一种靶向fgfr2的多肽核素配体、探针及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101420962A (zh) * | 2006-01-20 | 2009-04-29 | 星药股份有限公司 | 经修饰的大分子 |
| CN102089325A (zh) * | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| EP2453926A4 (en) * | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
| BR112013031556B1 (pt) * | 2011-06-06 | 2022-03-29 | Starpharma Pty Ltd | Macromoléculas, uso das mesmas para tratar ou suprimir o crescimento de um câncer e composições farmacêuticas |
| EP2885321A4 (en) * | 2012-08-14 | 2016-03-30 | Angiochem Inc | CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN |
| US9642916B2 (en) * | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
| US10550201B2 (en) * | 2013-03-13 | 2020-02-04 | Bioventures, Llc | Antibody-nanoparticle conjugates for the treatment of drug abuse |
| WO2017075171A2 (en) * | 2015-10-27 | 2017-05-04 | The Johns Hopkins University | Pamam dendrimer based cest imaging agents and uses thereof |
| EP3886912A4 (en) * | 2018-11-29 | 2023-01-04 | Starpharma Pty Limited | DENDRIMER FOR THERAPY AND IMAGING |
-
2021
- 2021-06-03 AU AU2021284918A patent/AU2021284918A1/en active Pending
- 2021-06-03 WO PCT/AU2021/050554 patent/WO2021243415A1/en not_active Ceased
- 2021-06-03 CN CN202180049571.2A patent/CN115989039A/zh active Pending
- 2021-06-03 US US17/928,306 patent/US20240293588A1/en active Pending
- 2021-06-03 JP JP2022574600A patent/JP2023529640A/ja active Pending
- 2021-06-03 KR KR1020227046150A patent/KR20230065935A/ko active Pending
- 2021-06-03 CA CA3180877A patent/CA3180877A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240216525A1 (en) | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties | |
| JP5084267B2 (ja) | 多特異性抗体との使用のための治療および診断用コンジュゲート | |
| JP6677489B2 (ja) | 増強された薬理学的性質を有する活性物質を送達するための方法および組成物 | |
| JP2022525704A5 (enExample) | ||
| JP2008546792A5 (enExample) | ||
| JP2018127469A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| JP2013100314A5 (enExample) | ||
| JP2022547434A5 (enExample) | ||
| US20240293588A1 (en) | Therapeutic conjugates | |
| CN109963620A (zh) | 细胞靶向缀合物 | |
| US20190216945A1 (en) | Antibody-polymer-drug conjugates | |
| JP2006507803A5 (enExample) | ||
| JP2024501894A5 (enExample) | ||
| JP2008515889A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| JP2022513630A5 (enExample) | ||
| RU2007116973A (ru) | Терапевтические средства с пониженной токсичностью | |
| JP2019524640A5 (enExample) | ||
| JP2016509586A5 (enExample) | ||
| JP2011505371A5 (enExample) | ||
| Liu et al. | Utility of 131I-HLX58-Der for the precision treatment: evaluation of a preclinical radio-antibody-drug-conjugate approach in mouse models | |
| Zalutsky et al. | Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent | |
| US20240091372A1 (en) | Anti-doppel antibody drug conjugates | |
| KR20010072988A (ko) | 이중작용기성 항체 및 항종양제를 표적화하기 위한 이들의용도 |